Kori L Wallace

发表

Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis

S. Targan, C. Pothoulakis, H. Koon, 2014, Mucosal Immunology.

Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease.

J. Linden, Kori L Wallace, Kori L. Wallace, 2010, Blood.

P-Selectin–Mediated Platelet-Neutrophil Aggregate Formation Activates Neutrophils in Mouse and Human Sickle Cell Disease*

R. Polanowska-Grabowska, J. Linden, J. Field, 2010, Arteriosclerosis, thrombosis, and vascular biology.

NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.

R. Strieter, J. Linden, J. Lannigan, 2009, Blood.

Immunopathology of inflammatory bowel disease.

Kori L Wallace, D. Shih, Y. Kanazawa, 2014, World journal of gastroenterology.

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

A. Kaser, O. Dewit, D. Franchimont, 2018, The lancet. Gastroenterology & hepatology.

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

D. Hommes, S. Travis, G. D'Haens, 2017, The Lancet.

SUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS.

S. Targan, C. Pothoulakis, H. Koon, 2013, European journal of microbiology & immunology.

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials

L. Peyrin-Biroulet, E. Loftus, J. Panés, 2022, Alimentary pharmacology & therapeutics.

Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation.

J. Linden, Kori L Wallace, Melissa A. Marshall, 2008, American journal of physiology. Heart and circulatory physiology.

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

A. Kaser, O. Dewit, G. D'Haens, 2021, Journal of Crohn's & colitis.

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

M. Kamm, S. Travis, J. Zhong, 2016, Intestinal research.

Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm

P. Rutgeerts, D. Hommes, S. Travis, 2017 .

Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn’s Disease Who Lost Response to Maintenance Therapy

T. Hibi, Mamoru Watanabe, N. Mostafa, 2018, Inflammatory Intestinal Diseases.

Leukocyte compartments in the mouse lung: distinguishing between marginated, interstitial, and alveolar cells in response to injury.

J. Linden, B. Mehrad, Kori L Wallace, 2012, Journal of immunological methods.

Research : Focus on Platelets P-Selectin – Mediated Platelet-Neutrophil Aggregate Formation Activates Neutrophils in Mouse and Human Sickle Cell Disease *

R. Polanowska-Grabowska, J. Linden, Kori L Wallace, 2010 .

Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.

P. Rutgeerts, Qian Zhou, W. Sandborn, 2018, Inflammatory bowel diseases.

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

M. Dubinsky, D. Rubin, G. D'Haens, 2022, The Lancet.

Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.

P. Rutgeerts, D. Rubin, J. Lewis, 2019, Inflammatory bowel diseases.

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease

E. Loftus, J. Griffith, Kori L Wallace, 2023, Advances in therapy.

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

M. Dubinsky, D. Rubin, G. D'Haens, 2022, The Lancet.

Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation.

J. Linden, Kori L Wallace, Melissa A. Marshall, 2008, American journal of physiology. Heart and circulatory physiology.

S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn’s Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy

M. Dubinsky, Kori L Wallace, Edward V Loftus, 2022, American Journal of Gastroenterology.

OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study

A. Kaser, O. Dewit, G. D'Haens, 2020 .

S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction

G. D'Haens, R. Panaccione, S. Danese, 2022, American Journal of Gastroenterology.

783 TL1A Modulates the Differential Effect of IL-17 Blockade on Mucosal Inflammation

S. Targan, C. Pothoulakis, H. Koon, 2014 .

775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study

D. Rubin, G. D'Haens, J. Lindsay, 2021, Gastroenterology.

Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn’s Disease: Results From a Randomised Phase II Biopsy Sub-study

R. Schmid, K. Grebe, J. Panés, 2018, Journal of Crohn's & colitis.

Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis

A. Ananthakrishnan, S. Danese, Kori L Wallace, 2023, PharmacoEconomics - Open.

DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials

L. Peyrin-Biroulet, E. Loftus, J. Griffith, 2021 .

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial

B. Feagan, R. Panaccione, Kori L Wallace, 2023, Journal of Crohn's & colitis.